Celldex posts press release on Phase 2 barzolvolimab results in prurigo nodularis
CLDX•Phase 2 barzolvolimab results in prurigo nodularis
- Celldex released Phase 2 topline data for barzolvolimab in prurigo nodularis; the study missed the primary endpoint at Week 12.
- Key secondary endpoints also missed; results did not separate from placebo on itch or lesion measures through Week 24.
- Celldex discontinued the Phase 2 prurigo nodularis program; safety was consistent with prior studies despite marked serum tryptase reductions.
